Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women

Human Immunodeficiency Virus Clinical Trial

Official title:

Phase 2a Safety Study of a Vaginal Matrix Ring Containing Dapivirine in a Postmenopausal Female Population

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02010593
• Other study ID #: MTN-024/IPM031
• Secondary ID: 5UM1AI068633-07
• Status: Completed
• Phase: Phase 2
• Start date: December 2013
• Est. completion date: April 2015

Study information

• Verified date: November 2022
• Source: International Partnership for Microbicides, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety of the dapivirine vaginal ring when inserts once every 4 weeks in postmenopausal women over 12 weeks of product use.

Description:

Dapivirine, a non-nucleoside reverse-transcriptase inhibitor (NNRTI), is a substituted diamino- pyrimidine (DAPY) derivative with potent antiviral activity against HIV-1. Dapivirine is chemically described as 4-[[4-[(2,4,6-trimethylphenyl)amino]-2- pyrimidinyl]amino]benzonitrile.6 The dapivirine matrix VR is a flexible ring containing 25 mg of drug substance dispersed in a platinum-catalyzed-cured silicone matrix. Dapivirine is known to be well-suited for delivery via VR, as evidenced by favorable safety and pharmacokinetic data to date described below.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 96
• Est. completion date: April 2015
• Est. primary completion date: April 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 45 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Age 45 through 65 years (inclusive) at Screening, verified per site SOPs

2. Per participant report, postmenopausal at Screening, defined as amenorrhoeic for the past 12 months (minimum) or at least 6 months status post-bilateral oophorectomy

3. Follicle-stimulating hormone (FSH) level at 40 mIU/ml or higher at Screening

4. Able and willing to provide written informed consent to be screened for and enrolled in MTN-024/IPM 031

5. Able to communicate in spoken and written English

6. Able and willing to comply with all study procedural requirements

7. Willing to only use study provided and/or approved vaginal products throughout the duration of study participation.

8. Willing to abstain from inserting study approved lubricant into the vagina for 72 hours prior to each visit

9. Willing to abstain from vaginal intercourse for 72 hours prior to each visit

10. In general good health as determined by the Investigator of Record (IoR)/designee at Screening and Enrollment

11. Able and willing to provide adequate locator information, as defined in site SOPs

12. HIV-uninfected based on testing performed at Screening (per protocol algorithm in Appendix II)

13. Per participant report at Screening and Enrollment, agrees to use male latex condoms for sexual intercourse

14. Per participant report at Screening and Enrollment, states a willingness to refrain from inserting any non-study vaginal products or objects into the vagina including, but not limited to spermicides, female condoms, diaphragms, topical or systemic hormone replacement therapy, including vaginal estrogens, and/or hormonal contraceptives, vaginal medications, menstrual cups, cervical caps (or any other vaginal barrier method), vaginal douches, lubricants and moisturizers, sex toys (vibrators, dildos, etc.), for the duration of the study participation.

Note: Use of study approved lubricant is permitted.

15. At Screening and Enrollment, agrees not to participate in other research studies involving drugs, medical devices, vaginal products, or vaccines for the duration of study participation

Participants in the biopsy subset must also meet the following criteria at Screening to be eligible for inclusion:

16. Willing to abstain from inserting anything into the vagina for 72 hours following the collection of biopsies, including abstaining from vaginal intercourse

17. Anatomy sufficient for the collection of cervical biopsies

Exclusion Criteria:

1. Per participant report at screening:

1. Plans to relocate away from the study site during study participation

2. Plans to travel away from the study site for more than 4 consecutive weeks during study participation

2. Pregnant at screening Note: A documented negative pregnancy test performed by study staff is required for inclusion; however a self-reported pregnancy is adequate for exclusion from the study.

3. Diagnosed with urinary tract infection (UTI) at Screening or Enrollment Note:

Otherwise eligible participants diagnosed with UTI during screening are offered treatment and may be enrolled after completing treatment and all symptoms have resolved.

If treatment is completed and symptoms have resolved within 45 days of obtaining informed consent for screening, the participant may be enrolled.

4. Diagnosed with pelvic inflammatory disease, an STI or reproductive tract infection (RTI) requiring treatment per current Centers for Disease Control and Prevention (CDC) guidelines at Screening or Enrollment Note: Otherwise eligible participants diagnosed during screening with pelvic inflammatory disease or STI/RTI requiring treatment per CDC guidelines - other than asymptomatic bacterial vaginosis (BV) and asymptomatic candidiasis - are offered treatment and may be enrolled after completing treatment and all symptoms have resolved. If treatment is completed and symptoms have resolved within 45 days of obtaining informed consent for screening, the participant may be enrolled. Genital warts requiring treatment also must be treated prior to Enrollment. Genital warts requiring therapy are defined as those that cause undue burden or discomfort to the participant, including bulky size, unacceptable appearance, or physical discomfort.

5. Has a clinically apparent Grade 2 or higher pelvic exam finding (observed by study staff) at Screening or Enrollment, as per the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Version 1.0, December, 2004 (Clarification dated August 2009), Addendum 1-Female Genital Grading Table for Use in Microbicide Studies Note: Cervical bleeding associated with speculum insertion and/or specimen collection judged to be within the range of normal according to the clinical judgment of the Investigator of Record (IoR)/designee is considered expected non-menstrual bleeding and is not exclusionary.

Note: Otherwise eligible participants with exclusionary pelvic exam findings may be enrolled/randomized after the findings have improved to a non-exclusionary severity grading or resolved. If improvement to a non-exclusionary grade or resolution is documented within 45 days of providing informed consent for screening, the participant may be enrolled.

6. Participant report and/or clinical evidence of any of the following:

1. Known adverse reaction to any of the study products (ever)

2. Known adverse reaction to latex (ever)

3. Chronic and/or recurrent vaginal candidiasis

4. Topical or systemic hormone replacement therapy and/or hormonal contraception within the 6 months prior to Enrollment

5. Non-therapeutic injection drug use in the 12 months prior to Enrollment

6. Post-exposure prophylaxis (PEP) for HIV exposure within the 6 months prior to Enrollment

7. Pre-exposure prophylaxis (PrEP) for HIV prevention within the 6 months prior to Enrollment

8. Last pregnancy outcome 6 months or less prior to Enrollment

9. Gynecologic or genital procedure (e.g., tubal ligation, dilation and curettage, piercing) 90 days or less prior to Enrollment

10. Currently breastfeeding

11. At Screening, severe pelvic relaxation such that either the vaginal walls or the uterine cervix descend beyond the vaginal introitus with Valsalva maneuver

12. Participation in any other research study involving drugs, medical devices, vaginal products, or vaccines, in the 45 days prior to Enrollment

7. As determined by the IoR/designee, any significant uncontrolled active or chronic cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, endocrine, respiratory, immunologic disorder or infectious disease

8. Has any of the following laboratory abnormalities at Screening Visit:

1. Aspartate aminotransferase (AST) or alanine transaminase (ALT) Grade 1 or higher*

2. Creatinine Grade 2 or higher*

3. Hemoglobin Grade 2 or higher*

4. Platelet count Grade 1 or higher*

5. Pap result Grade 2 or higher** Note: Otherwise eligible participants with an exclusionary test may be re-tested during the screening process.

Note: Women with a documented normal result within the 12 months prior to Enrollment need not have a Pap smear during the screening period. Women with a Grade 1 abnormal Pap smear can be enrolled upon completion of the initial phase of evaluation if no current treatment is indicated (based on local standard of care for management of abnormal cervical cytology). Need for a repeat Pap within 6 months does not preclude Enrollment prior to that result becoming available. If the participant has had a hysterectomy for reasons not related to cervical dysplasia, a Pap smear need not be performed.

9. Has any other condition that, in the opinion of the IoR/designee, would preclude informed consent, make study participation unsafe, complicate the interpretation of study outcome data, or otherwise interfere with achieving the study objectives *Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Version 1.0, December, 2004 (Clarification dated August 2009) **Female Genital Grading Table for Use in Microbicide Studies Addendum 1 to the Division of AIDS (DAIDS) Table for Grading Adult and Pediatric Adverse Events, Version 1.0, December 2004 (Clarification dated August 2009)

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• HIV Infections
• Human Immunodeficiency Virus

Intervention

Drug:
• Dapivirine Vaginal Ring
Dapivirine, a non-nucleoside reverse-transcriptase inhibitor (NNRTI), is a substituted amino- pyrimidine (DAPY) derivative with potent antiviral activity against HIV-1. Dapivirine is chemically described as 4-[[4-[(2,4,6-trimethylphenyl)amino]-2- pyrimidinyl]amino]benzonitrile.6 The dapivirine matrix VR is a flexible ring containing 25 mg of drug substance dispersed in a platinum-catalyzed-cured silicone matrix. Dapivirine is known to be well-suited for delivery via VR
• Placebo Vaginal Ring
The placebo VR is a flexible, platinum-catalyzed-cured silicone matrix ring, identical to dapivirine Ring-004, containing no active drug.

Locations

Country	Name	City	State
United States	Alabama CRS, 84519th Street South, BBRB 203A	Birmingham	Alabama
United States	Case CRS, Case Western Reserve University, 2061 Cornell Road, Room 303	Cleveland	Ohio
United States	Magee Women's Hospital of UPMC	Pittsburgh	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
International Partnership for Microbicides, Inc.	National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of Dapivirine (25 mg) Administered in a Silicone Elastomer Vaginal Matrix Ring in HIV-uninfected Postmenopausal Women, When Inserted Once Every 4 Weeks During 12 Weeks of Study Product Use	Evidence of Grade 2 or higher genital, genitourinary and reproductive system AEs as defined by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, Dec 2004 (Clarification dated August 2009), Addendum 1, (Female Genital Grading Table for Use in Microbicide Studies) judged to be related to study product.; Evidence of Grade 3 or higher AEs as defined by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, Dec 2004 (Clarification dated August 2009).; DAIDS severity grades are defined as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = potentially life-threatening; Grade 5 = death	over 12-week period of use
Secondary	The Percentage of Participants Who Find the Study Vaginal Ring to be as Acceptable	To evaluate the acceptability, the percentage of participants who at their 12-Week Final Clinic Visit report via acceptability questionnaire that they prefer the ring at least as much as other HIV prevention methods.	at 12-week visit
Secondary	Percentage of Women Who Were Adherent to Daily Study Product Use Based on Self-report Over the 12-week Study Product Use Period	Adherence will be measured by the percentage of women who keep the VR inserted at all times in the vagina over the course of 12 weeks.; A participant was considered adherent in one month (4 weeks) by self-reported data, only if the ring was never out during that month and the participant was not on product hold and did not terminate the clinical trial within that month.	12-week period of use
Secondary	Pharmacokinetics - The Intent is to Determine if the Plasma Dapivirine Concentrations Are Different in Postmenopausal Women Than in Pre-menopausal Adult Women After Placement of Dapivirine Vaginal Rings.	The PK endpoint is a description of the end of period (28 day post ring insertion) plasma dapivirine concentrations at week 4, 8, and 12 which will be compared to the same results in a recently studied population of premenopausal adult women (MTN-013).	a 12 week product use period
Secondary	Pharmacokinetics - The Intent is to Determine if the Vaginal Fluid Dapivirine Concentrations Are Different in Postmenopausal Women Than in Pre-menopausal Adult Women After Placement of Dapivirine Vaginal Rings.	The PK endpoint is a description of the end of period (28 day post ring insertion) vaginal fluid dapivirine concentrations at week 4, 8, and 12 which will be compared to the same results in a recently studied population of premenopausal adult women (MTN-013).	a 12 week product use period